Fig. 5From: Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myelomaCost-effectiveness acceptability curve based on ICUR between DRd and KRd. The horizontal axis displays the willingness-to-pay budgetary thresholds to gain one additional QALY when using DRd, and the vertical axis displays the percentage of 10,000 patients that fall within the available budgetBack to article page